Hematology and Covid-19

COVID-19 is a systemic disease with a significant impact on the hematopoietic system and hemostasis. Patients with cancer may be huge susceptible to and have higher morbidity and mortality rates from COVID-19 than the general population, while epidemiologic data specifically addressed to hematologic patients are limited. The prevalence of COVID-19 in hematologic patients, mostly affected by malignancies, was not significantly higher compared to that of the general population. The revision enlightens on the epidemiology, risk factors and outcomes of COVID-19 among patients with HM. While the COVID-19 vaccinations will lead to a marked reduction of infections in HM patients, the possibility of a lower efficacy of vaccinations needs to be taken into account and possibly resembling previous experiences with influenza vaccination. 

Related TagsHematology ConferenceHematology conferences 2024Hematology conferences Hematology conferences 2024 | Hematology CongressHematology Congress 2024Hematology meetingsHematology meeting 2024Hematology summit | Hematology summit 2024Leukemia conferenceLeukemia conferencesLeukemia conference 2024Leukemia conferences 2024Leukemia congressLeukemia congress 2024Leukemia meetingLeukemia meetingsLeukemia meeting 2024Leukemia meetings 2024Leukemia summit | Leukemia summit 2024Lymphoma congress Lymphoma congress 2024Lymphoma summitLymphoma summit 2024Lymphoma meeting | Lymphoma meeting 2024 | MyelofibrosisMyelofibrosis 2024Myelofibrosis congress Myelofibrosis congress  2024

Related AssociationsHematology/Oncology Pharmacy Association | Hospice & Palliative Nurses Association | Institute of Medicine of the National Academies | International Association of Cancer Registries | International Association for the Study of Lung Cancer | International Collaboration on Cancer ReportingInternational Extranodal Lymphoma Study Group | International Federation of Head and Neck Oncologic SocietiesInternational Gynecologic Cancer Society